Surveillance for early diagnosis of hepatocellular carcinoma: Is it effective in intermediate/advanced cirrhosis?

American Journal of Gastroenterology

Volumn 102, Issue 11, 2007, Pages 2448-2457

  Trevisani, Franco ^a,i   Santi, Valentina ^a   Gramenzi, Annagiulia ^a   Di Nolfo, Maria Anna ^b   Poggio, Paolo Del ^c   Benvegnù, Luisa ^d   Rapaccini, Gianludovico ^e   Farinati, Fabio ^d   Zoli, Marco ^a   Borzio, Franco ^f   Giovanni Giannini, Edoardo ^g   Caturelli, Eugenio ^h   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BOLOGNINI HOSPITAL   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f FATEBENEFRATELLI HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h BELCOLLE HOSPITAL   (Italy)

ⁱ Dipartimento di Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; FEMALE; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 35448980255     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01395.x     Document Type: Article

References (34)

1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004 127 : 5 16.
2. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001 33 : 62 5.
3. Chalasani N, Horlander JC Sr., Said A, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999 94 : 2988 93.
4. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003 39 : 1076 84.
5. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004 127 : 35 50.
6. Yuen MF, Cheng CC, Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000 31 : 330 5.
7. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost-effectiveness analysis. Gut 2001 48 : 251 9.
8. Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: Effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002 97 : 734 44.
9. Marrero J, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002 36 : 1349 54.
10. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004 126 : 1005 14.
11. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 30.
12. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 36.
13. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating hepatocellular carcinoma among medicare recipients in the United States: A population-based study. J Hepatol 2006 340 : 745 50.
14. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996 101 : 422 34.
15. Pugh NH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 60 : 646 9.
16. Bruix J, Llovet JM. Hepatocellular carcinoma: Is surveillance cost effective? Gut 2001 48 : 149 50.
17. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 362 : 1907 17.
18. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005 129 : 122 30.
19. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005 54 : 1151 6.
20. Trevisani F, De Notariis S, Rossi C, et al. Randomized control trials on chemoembolization for hepatocellular carcinoma: Is there room for new studies? J Clin Gastroenterol 2001 32 : 383 9.
21. Commissione "Epatocarcinoma" dell'Associazione Italiana per lo Studio del Fegato. Epatocarcinoma: Linee Guida per la Diagnosi e la Terapia. Bologna : Tipografia Moderna, 1998.
22. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999 19 : 329 38.
23. Adams PC, Arthur MJ, Boyer TD, et al. Screening in liver disease: Report of an AASLD clinical workshop. Hepatology 2004 39 : 1204 12.
24. Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993 72 : 1557 63.
25. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000 31 : 840 5.
26. Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: Effects on cancer staging and patients survival. Am J Gastroenterol 2004 99 : 1470 6.
27. Shwartz MA. Biomathematical approach to clinical tumor growth. Cancer 1961 14 : 1272 94.
28. Scheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985 89 : 259 66.
29. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: What is a clinically significant gain? J Gen Intern Med 1994 9 : 702 7.
30. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996 334 : 693 9.
31. Majno P, Giostra E, Morel P, et al. For the Geneva Liver Cancer Study Group. Management of hepatocellular carcinoma in the waiting list before liver transplantation. J Hepatol 2005 42 : 134 43.
32. Tinetti ME, Bogardus ST Jr., Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004 351 : 2870 4.
33. Sorensen HF, Lash TL, Rothman KJ. Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies. Hepatology 2006 44 : 1075 82.
34. Ray WA. Observational studiers of drugs and mortality. N Engl J Med 2005 353 : 2319 21.